Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.
1. A crystalline form of (2R,6R)-hydroxynorketamine hydrochloride
wherein the crystalline form of (2R,6R)-hydroxynorketamine hydrochloride is characterized by
exhibiting a XRPD spectra with characteristic peaks at any combination of at least 5, at least 8, at least 10, or at least 12 of the following (2θ) values: 12.1, 13.6, 14.1, 15.1, 15.6, 16.9, 18.0, 19.2, 19.5, 20.8, 22.1, 23.5, 24.0, 24.3, 24.6, 24.8, 25.2, 26.4, 27.0, 27.4, 27.7, 28.1, 29.9, 30.2, 31.5, 31.9, 32.4, 32.7, 33.5, 34.7, 36.5, 37.1, 37.7, 38.3, 38.7, 39.1, and 39.6.
2. The crystalline form of claim 1 , wherein the crystalline form contains no detectable amounts of other hydroxynorketamine or hydroxynorketamine salts crystalline forms as determined by x-ray powder diffraction.
3. The crystalline form of (2R,6R)-hydroxynorketamine hydrochloride of claim 1 ,
wherein the crystalline form is characterized by single crystal parameters approximately equal to the following:
cell dimensions comprising a=7.35 Å alpha=90°
b=7.49 Å beta=96.87°
c=11.35 Å gamma=90°
V=621.02 Å 3 ; and
space group=P 1 21 1, crystal system=monoclinic, molecules per unit cell=1, density (calculated)=1.477 mg/m 3 .
4. A crystalline form of (2R,6R)-hydroxynorketamine exhibiting a XRPD spectra as shown in FIG. 3 .